GENETETHER THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.05 CAD | 0.00% |
|
+150.00% | +25.00% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 3.536 | 1.169 |
| Enterprise Value (EV) 1 | 1.74 | -0.1946 |
| P/E ratio | -1.84 x | -2.03 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | -32,30,674 x | 8,21,727 x |
| FCF Yield | -0% | 0% |
| Price to Book | 1.91 x | 0.85 x |
| Nbr of stocks (in thousands) | 48,179 | 38,745 |
| Reference price 2 | 0.0734 | 0.0302 |
| Announcement Date | 27/04/23 | 29/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -0.0816 | -0.0862 | -0.072 | -1.637 | -1.717 | -0.7473 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.0816 | -0.0867 | -0.073 | -1.638 | -1.715 | -0.6884 |
| Net income 1 | -0.0816 | -0.0867 | -0.073 | -1.638 | -1.715 | -0.6884 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.1666 | -0.1235 | -0.1012 | -0.0458 | -0.0398 | -0.0148 |
| Free Cash Flow | - | -0.0632 | -0.0426 | -0.1262 | -0.5387 | -0.2368 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 04/11/21 | 04/11/21 | 28/04/22 | 27/04/23 | 29/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.01 | 0.08 | - | - | - |
| Net Cash position 1 | 0.03 | - | - | 0.18 | 1.8 | 1.36 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -0.06 | -0.04 | -0.13 | -0.54 | -0.24 |
| ROE (net income / shareholders' equity) | - | -1,700% | 170% | -4,122% | -170% | -42.6% |
| ROA (Net income/ Total Assets) | - | -259% | -154% | -492% | -92.7% | -27.8% |
| Assets 1 | - | 0.0335 | 0.0475 | 0.3328 | 1.85 | 2.472 |
| Book Value Per Share 2 | 0.0400 | -0.0100 | -0.1000 | 0 | 0.0400 | 0.0400 |
| Cash Flow per Share 2 | 0.0500 | 0.0100 | 0.0600 | 0 | 0.0400 | 0.0400 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 04/11/21 | 04/11/21 | 28/04/22 | 27/04/23 | 29/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +25.00% | 1.42M | |
| +38.36% | 52.5B | |
| +36.73% | 39.31B | |
| -8.63% | 39.01B | |
| +25.46% | 28.2B | |
| -11.17% | 26.57B | |
| +11.44% | 26.2B | |
| +45.09% | 14.15B | |
| +32.93% | 12.62B | |
| -5.30% | 11.74B |
- Stock Market
- Equities
- GTTX Stock
- Financials GeneTether Therapeutics Inc.
